Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055575 · ClinicalTrials.gov registry record · Phase 2
Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT00055575 is a Phase 2 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 197 participants.
The verdict
NCT00055575, a Phase 2 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
Interventions
- DRUG Scopolamine Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2003-02-27 |
| Est. Completion | 2015-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055575
The ClinicalTrials.gov registry entry for NCT00055575 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Scopolamine Nasal Spray is the first listed.
NCT00055575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055575 about?
NCT00055575 is a clinical study titled "Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies". This study looks at the role of a specific brain chemical system in the mood and attention symptoms seen in major depression and bipolar disorders using functional brain imaging.
What is the current status of trial NCT00055575?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2003-02-27. Estimated completion is 2015-02-02.
What interventions are being tested in trial NCT00055575?
The interventions under investigation include: Scopolamine Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT00055575?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.